戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ence was reported for groups with at least 1 neurological manifestation.
2 be a worldwide health concern connected with neurological manifestations.
3 ndrial disease that is often associated with neurological manifestations.
4 lthy controls, including those without overt neurological manifestations.
5  disease 2019 (COVID-19) patients experience neurological manifestations.
6 ternative therapeutic targets for late-stage neurological manifestations.
7  severe placental damage leading to neonatal neurological manifestations.
8 iated with this syndrome include uveitis and neurological manifestations.
9 VID-19 severity score) with COVID-19 without neurological manifestations.
10 ic disorder that is associated with multiple neurological manifestations.
11 oduction defects that frequently have severe neurological manifestations.
12 was met with increased reports of associated neurological manifestations.
13 iciency disorders, characterized by variable neurological manifestations.
14  in patients presenting with fever and acute neurological manifestations.
15 were reviewed to identify those with primary neurological manifestations.
16 y recurrent hemiplegic episodes and distinct neurological manifestations.
17 oth males and females, and in some patients, neurological manifestations.
18 hen synucleinopathy occurs in the absence of neurological manifestations.
19 euroserpin inclusion bodies but with various neurological manifestations.
20 r disease, but no therapies are approved for neurological manifestations.
21 rombocytopenia, skeletal disease and diverse neurological manifestations.
22 nial nerve dysfunctions were the most common neurological manifestations.
23 ized patients with COVID-19 with and without neurological manifestations; (2) the GCS-NeuroCOVID COVI
24 discharge compared with those without severe neurological manifestations (27.7% [n = 142] vs 14.6% [n
25  effects of GD, the lack of efficacy for the neurological manifestations, along with the considerable
26  414 patients with COVID-19 with significant neurological manifestations and 1,199 propensity-matched
27 ial morphology associated with heterogeneous neurological manifestations and cognitive and behavioral
28  hospitalized with COVID-19 and assessed for neurological manifestations and complications were inclu
29                    This Review discusses the neurological manifestations and emerging therapies for t
30 nclusion, adults and children have different neurological manifestations and in-hospital complication
31      We aimed to determine the prevalence of neurological manifestations and in-hospital complication
32                                  Analyses of neurological manifestations and neurological complicatio
33 e purine pathway, is characterized by severe neurological manifestations and uric acid overproduction
34 ian sub-continent, recurring sporadic cases, neurological manifestation, and high mortality rate of t
35 ar Purkinje cell loss, slowed progression of neurological manifestations, and increased lifespan in m
36 hospitalized with COVID-19 who had confirmed neurological manifestations; and (3) the ENERGY cohort (
37                                              Neurological manifestations are a significant complicati
38 al presentation is with respiratory disease, neurological manifestations are being recognised increas
39 nterventions for patients with COVID-19 with neurological manifestations, as their disease course inv
40 cians are attempting to further characterise neurological manifestations associated with mutations in
41 utations in TSC1 or TSC2 may lead to certain neurological manifestations associated with the disease.
42 ecal HPbetaCD to participants with NPC1 with neurological manifestation at the National Institutes of
43    In adults and children, the most frequent neurological manifestations at admission were fatigue (a
44 usting for risk factors in those with severe neurological manifestations, both patients with acute SA
45  people globally, with increasing reports of neurological manifestations but limited data on their in
46  There is a wide and overlapping spectrum of neurological manifestations caused by Zika or chikunguny
47 ns characterized by hemorrhagic fever and/or neurological manifestations, constituting public health
48 h acute SARS-CoV-2, 536 (18.0%) had a severe neurological manifestation during hospitalization, as di
49                                              Neurological manifestations during acute SARS-CoV-2-rela
50 mes of patients with and without significant neurological manifestations during initial COVID-19 hosp
51                                              Neurological manifestations ensue from primary loss of d
52           Furthermore, HEV can cause diverse neurological manifestations, especially Parsonage-Turner
53 gen targets that plausibly explained several neurological manifestations; for example, P/Q-type Ca(2+
54 ivors with MIS-C, 28.0% (n = 39) with severe neurological manifestations had new neurocognitive and/o
55                  Patients with COVID-19 with neurological manifestations had worse long-term outcomes
56 ficantly higher in severe malaria cases with neurological manifestations (ie, coma, impaired consciou
57 uminated the social impact, psychopathology, neurological manifestation, immunity responses, and pote
58  reports and series describe a wide array of neurological manifestations in 901 patients, but many ha
59                                              Neurological manifestations in 95 patients were (in decr
60                        However, a variety of neurological manifestations in both adults and newborns
61                                     Although neurological manifestations in patients with established
62 eptor regulation, which likely contribute to neurological manifestations in SLOS patients.
63 uidelines that, for the first time, consider neurological manifestations in the clinical case classif
64                  Prevalence of non-cognitive neurological manifestations in the DIAN-OBS cohort was l
65 histone modifications in contributing to the neurological manifestations in TSC.
66 ) has been noted for its tendency to lead to neurological manifestations in young children and infant
67 ic purpura (TTP) is a syndrome with numerous neurological manifestations including altered mental sta
68 elopment of hamartomas in various organs and neurological manifestations including epilepsy, intellec
69 e sequencing on a cohort of 38 children with neurological manifestations, including VZV encephalitis,
70                                              Neurological manifestations (information available for 3
71 set (Spanish Cohort A) or by the time of new neurological manifestations (international Cohort B).
72  syndrome coronavirus 2 (SARS-CoV-2)-related neurological manifestations involve cytokine release syn
73                                        Acute neurological manifestation is a common complication of a
74                              Its most severe neurological manifestation is cerebral adrenoleukodystro
75 s, as their disease course involving initial neurological manifestations is associated with enhanced
76 assess if therapy aimed at the prevention of neurological manifestations is warranted.
77          Clinicoradiological features of its neurological manifestations, its prognosis, and the freq
78                              The spectrum of neurological manifestations linked to these viruses, and
79  and progressive clinical features and other neurological manifestations, linked with magnetic resona
80 ts with acute SARS-CoV-2 or MIS-C and severe neurological manifestations may be at high risk for long
81                           Additional diverse neurological manifestations may dominate the clinical pi
82  (n = 98); (3) MG plus additional autoimmune neurological manifestations (n = 26); and (4) neurologic
83 Despite typically presenting with pronounced neurological manifestations, NP-C1 also resembles long-t
84                 Sydenham chorea is the major neurological manifestation of ARF but its pathogenesis h
85                      Ataxia is the commonest neurological manifestation of coeliac disease.
86                                     The main neurological manifestation of COVID-19 is loss of smell
87 ght into molecular mechanisms underlying the neurological manifestation of diseases associated with i
88             Lyme neuroborreliosis (LNB), the neurological manifestation of systemic infection with th
89 eficiency of research and information on the neurological manifestation of the disease.
90  enzyme replacement therapy to treat the non-neurological manifestations of ASMD.
91                   These disorders have other neurological manifestations of central/peripheral hypere
92                                              Neurological manifestations of complex humanitarian emer
93                                    Different neurological manifestations of coronavirus disease 2019
94 e is an accumulating volume of research into neurological manifestations of COVID-19.
95 ortant mediator of both short- and long-term neurological manifestations of COVID-19.
96 ss of the sense of smell, is one of the main neurological manifestations of COVID-19.
97                                          The neurological manifestations of CTLA4h are poorly charact
98 t appear to have significant benefits on the neurological manifestations of GD3.
99 n this Personal View, we review the range of neurological manifestations of gluten sensitivity and di
100                                              Neurological manifestations of HCV infection include fat
101     This has had a significant impact on the neurological manifestations of HIV infection, posing new
102                  In addition to the hallmark neurological manifestations of Huntington's disease (HD)
103                         We aimed to describe neurological manifestations of influenza in adults and c
104 scribed a cohort of adults and children with neurological manifestations of influenza.
105                                              Neurological manifestations of Lyme disease are usually
106                                              Neurological manifestations of Lyme disease in humans ar
107            Development of treatments for the neurological manifestations of MPS has been hindered by
108 s and neurons allowed us to link a subset of neurological manifestations of MSD to astrocyte dysfunct
109 k provided a unique opportunity to study the neurological manifestations of ROCM and to investigate n
110                                          The neurological manifestations of sarcoidosis, which occur
111                             Amongst the many neurological manifestations of SLE, cognitive impairment
112            No treatment is available for the neurological manifestations of the disease.
113 system of patients with KSS accounts for the neurological manifestations of the disease.
114 multi-centre international study focusing on neurological manifestations of the largest cohort of Les
115 ing some pathogenic conundrums regarding the neurological manifestations of the respiratory chain def
116 ated disorders, focusing particularly on the neurological manifestations of these conditions.
117  combined with immunotherapy can improve the neurological manifestations of these patients.
118                                              Neurological manifestations of TSC include brain lesions
119 g potential therapeutic intervention for the neurological manifestations of TSC.
120 peutic interventions to alleviate the severe neurological manifestations of typhoid fever.
121 hout and were most frequent in patients with neurological manifestations other than or in addition to
122  with 15.5% (n = 68) of those without severe neurological manifestations (P = .002).
123 cism was associated with milder disease, yet neurological manifestations persisted in 3 individuals.
124 ficiency, many hospitalized patients exhibit neurological manifestations ranging from headache and lo
125  2 (SARS-CoV-2) leads to acute and long-term neurological manifestations remains obscure.
126 the common occurrence of gut dysmotility and neurological manifestations reminiscent of mitochondrial
127 f 3743 patients (82%) across cohorts had any neurological manifestation (self-reported neurological s
128 w that mice carrying this mutation developed neurological manifestations similar to those of human pa
129 tivated to result in herpes zoster or severe neurological manifestations such as encephalitis.
130 eat in FMR1 that presents with a spectrum of neurological manifestations, such as gait ataxia, intent
131 f mTOR signaling causes diseases with severe neurological manifestations, such as tuberous sclerosis
132 gnitive disorder (HAND) remains an important neurological manifestation that adversely affects a pati
133 chondrial diseases (PMDs) frequently exhibit neurological manifestations that overlap with other nerv
134     Recent reports have also indicated other neurological manifestations to be associated with ZIKV,
135                                      Primary neurological manifestations, unrelated to post-anoxic se
136  acid, the parent compound linked with human neurological manifestations was subjected to toxicologic
137 ors with acute SARS-CoV-2, those with severe neurological manifestations were more likely to have new
138                    In 3 patients, additional neurological manifestations were present, including inte
139                   In this multicohort study, neurological manifestations were prevalent among patient
140       As the COVID-19 pandemic developed and neurological manifestations were reported, concern grew
141                                       Severe neurological manifestations, which included acute enceph
142 rformed to examine the association of severe neurological manifestations with new morbidity in each S

 
Page Top